Suggested remit To appraise the clinical and cost effectiveness of selpercatinib within its marketing authorisation for treating advanced RET fusion-positive thyroid cancer and advanced RET mutation-positive medullary thyroid cancer (MTC).
Status In progress
Process STA 2018
ID number 3744

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
15 May 2020 - 15 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance